Findings

What do systematic reviews say?

2 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 60%Low 1 · 20%Moderate 1 · 20%High 0 · 0%

Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo

Everolimus + SSA (1 RCT; 39 participants)

Estimates of effects, ranking, and certainty of evidence for… may leads to lower everolimus + SSA (3 RCTs; 739 participants) compared with placebo (low certainty).

4 findings from 1 review

Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
HR 0.38 [0.26, 0.57]
3 studies · 739 participants
Low
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 15.1 [2.55, 88.9]
1 study · 39 participants
Very low
Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 2.89 [1.61, 5.19]
2 studies · 589 participants
Moderate

Show 1 more finding

Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
HR 0.12 [0.03, 0.54]
1 study · 39 participants
Very low

Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo

Everolimus + bevacizumab + SSA (1 RCT; 150 participants)

It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes everolimus + bevacizumab + SSA (1 RCT; 150 participants) compared with placebo (very low certainty).

1 finding from 1 review

Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only
HR 0.48 [0.28, 0.83]
1 study · 150 participants
Very low